Observational studyMedicine2026
Stellate ganglion block associated with changes in depression and anxiety in idiopathic sudden sensorineural hearing loss: A retrospective observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stellate Ganglion Block Combined with Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss: A Retrospective Three-Arm Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic sudden sensorineural hearing loss (ISSNHL) is often accompanied by depression and anxiety. Stellate ganglion block (SGB) is useful to treat ISSNHL by enhancing cochlear perfusion. Recently, SGB has been reported to improve depressive symptoms in posttraumatic stress disorder, but it remains unclear whether SGB can decrease depressive symptoms and anxiety in patients with ISSNHL. In this single-center retrospective observational study, 35 patients with ISSNHL were included. Patients were treated with dexamethasone, low-molecular-weight dextran, and SGB. Depressive and anxiety symptoms were assessed using the Beck depression inventory (BDI) and generalized anxiety disorder-7 (GAD-7) before treatment (baseline), 1 hour after the 1st SGB (1 H) and 30 days after treatment (30D). Auditory function was evaluated by pure-tone audiometry (PTA) before and 30 days after treatment. PTA threshold significantly improved at 30D (47.9 ± 27.7), compared to baseline (68.0 ± 23.2) (P < .001). The BDI significantly decreased at 1 H (5.5 ± 8.0) and 30D (4.5 ± 7.4), compared to baseline (9.1 ± 8.2) (P < .0001). The GAD-7 significantly decreased at 1 H (2.3 ± 3.0) and Day 30 (1.9 ± 2.6), compared to baseline (4.7 ± 3.6) (P < .0001). However, improvement in PTA is not correlated with improvement in BDI or GAD-7. SGB was associated with significant decreases in depressive and anxiety symptoms in patients with ISSNHL, which were not correlated with hearing recovery. These findings suggest that SGB may provide a potential benefit for mood improvement, independent of its effect on hearing recovery in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.